etodolac has been researched along with Ache in 23 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and tolerability of etodolac and indomethacin were compared in patients with osteoarthritis of the knee." | 9.07 | Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. ( Karbowski, A, 1991) |
| "A double-blind study was carried out to compare the effectiveness and tolerability of two non-steroidal anti-inflammatory drugs, etodolac and piroxicam, in patients with osteoarthritis of the knee." | 9.06 | A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. ( Freitas, GG, 1990) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 8.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)." | 8.78 | Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. ( Porzio, F, 1993) |
| "Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain." | 8.78 | Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. ( Balfour, JA; Buckley, MM, 1991) |
| "The effects of combined single oral treatments with non-steroidal anti-inflammatory drugs (NSAIDs) and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan (DM) on arthritic pain were examined in a rat model of adjuvant-induced arthritis." | 7.69 | Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. ( Caruso, FS; Frenk, H; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1996) |
| " Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than in the etodolac group: 23." | 6.67 | Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. ( Bogliolo, A; Perpignano, G; Puccetti, L, 1994) |
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | 6.38 | Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. ( Franchimont, P; Reginster, JY, 1993) |
| "Etodolac-paracetamol was significantly superior to etodolac alone in reducing pain intensity (P<0." | 5.14 | Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. ( Ambade, R; Bartakke, G; Chandanwale, A; Chandurkar, N; Pareek, A, 2010) |
| "The objective of this double-blind, randomized, parallel-group study was to evaluate the pharmacokinetics of etodolac and the pharmacodynamic response of pain in patients following oral surgery who had received 200 or 400 mg of etodolac immediate release (IR), 400 or 1200 mg of etodolac extended release (ER), or a placebo." | 5.09 | Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery. ( Appel, A; Boni, J; Cooper, S; Korth-Bradley, J; McGoldrick, K, 1999) |
| "The efficacy and tolerability of etodolac and indomethacin were compared in patients with osteoarthritis of the knee." | 5.07 | Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. ( Karbowski, A, 1991) |
| "A double-blind study was carried out to compare the effectiveness and tolerability of two non-steroidal anti-inflammatory drugs, etodolac and piroxicam, in patients with osteoarthritis of the knee." | 5.06 | A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. ( Freitas, GG, 1990) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 4.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| "A meta-analysis was done with the data from two studies that provided the first efficacy and safety results for the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis (RA)." | 4.78 | Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. ( Porzio, F, 1993) |
| "Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) effective in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis, and in the alleviation of postoperative pain." | 4.78 | Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. ( Balfour, JA; Buckley, MM, 1991) |
| " We have previously reported that etodolac, a nonsteroidal anti-inflammatory drug, attenuates mechanical allodynia in a mouse model of neuropathic pain by a mechanism that is independent of cyclooxygenase inhibition." | 3.78 | Etodolac blocks the allyl isothiocyanate-induced response in mouse sensory neurons by selective TRPA1 activation. ( Inoue, N; Ito, S; Kyoi, T; Nogawa, M; Tajima, K, 2012) |
| " Both etodolac and bromelain inhibited the inflammatory pain in concanavalin A-treated paws of rats in a dose-dependent manner, but indomethacin did not." | 3.69 | Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation. ( Dainaka, J; Hashii, H; Inoue, K; Kimura, K; Motonaga, A; Nishimura, T; Ueda, F; Yamate, K, 1994) |
| " Eto inhibited carrageenin-induced edema in rats, adjuvant-induced arthritis in rats, acetic acid-induced writhing in mice and brewer's yeast-induced hyperalgesia and fever in rats." | 3.69 | Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs. ( Fujisawa, H; Inoue, K; Inoue, Y; Kimura, K; Kyoi, T; Motonaga, A; Ueda, F, 1994) |
| "The effects of combined single oral treatments with non-steroidal anti-inflammatory drugs (NSAIDs) and the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan (DM) on arthritic pain were examined in a rat model of adjuvant-induced arthritis." | 3.69 | Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats. ( Caruso, FS; Frenk, H; Lu, J; Mao, J; Mayer, DJ; Price, DD, 1996) |
| " Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than in the etodolac group: 23." | 2.67 | Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. ( Bogliolo, A; Perpignano, G; Puccetti, L, 1994) |
| " This results in an increase in the rate of absorption of the active compound and, consequently, in an earlier onset of analgesic action." | 2.38 | Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. ( Franchimont, P; Reginster, JY, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 15 (65.22) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biava, M | 1 |
| Porretta, GC | 1 |
| Poce, G | 1 |
| Supino, S | 1 |
| Manetti, F | 1 |
| Forli, S | 1 |
| Botta, M | 1 |
| Sautebin, L | 1 |
| Rossi, A | 1 |
| Pergola, C | 1 |
| Ghelardini, C | 1 |
| Norcini, M | 1 |
| Makovec, F | 1 |
| Giordani, A | 1 |
| Anzellotti, P | 1 |
| Cirilli, R | 1 |
| Ferretti, R | 1 |
| Gallinella, B | 1 |
| La Torre, F | 1 |
| Anzini, M | 1 |
| Patrignani, P | 1 |
| Inoue, N | 2 |
| Ito, S | 2 |
| Tajima, K | 2 |
| Nogawa, M | 2 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kyoi, T | 3 |
| Pareek, A | 1 |
| Chandurkar, N | 1 |
| Ambade, R | 1 |
| Chandanwale, A | 1 |
| Bartakke, G | 1 |
| Lowenthal, MN | 1 |
| Tombak, A | 1 |
| Lowenthal, A | 1 |
| Abdel-Salam, OM | 1 |
| Clark, TP | 1 |
| Perpignano, G | 1 |
| Bogliolo, A | 1 |
| Puccetti, L | 1 |
| Inoue, K | 2 |
| Motonaga, A | 2 |
| Dainaka, J | 1 |
| Nishimura, T | 1 |
| Hashii, H | 1 |
| Yamate, K | 1 |
| Ueda, F | 2 |
| Kimura, K | 2 |
| Fujisawa, H | 1 |
| Inoue, Y | 1 |
| Reginster, JY | 1 |
| Franchimont, P | 1 |
| Porzio, F | 2 |
| Dreiser, RL | 1 |
| Bacon, P | 1 |
| Schumacher, HR | 1 |
| Meng, Z | 1 |
| Sieck, M | 1 |
| Zonay, L | 1 |
| Clayburne, G | 1 |
| Baker, JF | 1 |
| Park, J | 1 |
| Baker, DG | 1 |
| Price, DD | 1 |
| Mao, J | 1 |
| Lu, J | 1 |
| Caruso, FS | 1 |
| Frenk, H | 1 |
| Mayer, DJ | 1 |
| Boni, J | 1 |
| Korth-Bradley, J | 1 |
| McGoldrick, K | 1 |
| Appel, A | 1 |
| Cooper, S | 1 |
| Balfour, JA | 1 |
| Buckley, MM | 1 |
| Karbowski, A | 1 |
| Freitas, GG | 1 |
| Russo Frattasi, CA | 1 |
| Bevilacqua, R | 1 |
5 reviews available for etodolac and Ache
| Article | Year |
|---|---|
The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cats; Cyclooxygenase | 2006 |
Piroxicam-beta-cyclodextrin in the treatment of acute pain of rheumatic disease.
Topics: Acute Disease; Adult; beta-Cyclodextrins; Controlled Clinical Trials as Topic; Cyclodextrins; Diclof | 1993 |
Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Delay | 1993 |
Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Delayed-Action Prepa | 1993 |
Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Humans; Indoleace | 1991 |
9 trials available for etodolac and Ache
| Article | Year |
|---|---|
Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Cyclooxygenase Inhibitors; Double-Blind Method | 2010 |
Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Di | 1994 |
A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 1993 |
Worldwide experience with etodolac (Lodine) 300 mg b.i.d. in the treatment of osteoarthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Diclofenac; Double-Blind Me | 1993 |
Effect of a nonsteroidal antiinflammatory drug on synovial fluid in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Etodolac; Humans; Interleukin-6; Knee Joint; | 1996 |
Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double | 1999 |
Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Female; Humans; | 1991 |
A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Female; Humans; | 1990 |
[Open evaluation of a new anti-inflammatory analgesic drug: etodolac. Report of a clinical trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials | 1989 |
9 other studies available for etodolac and Ache
| Article | Year |
|---|---|
Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.
Topics: Acetic Acid; Alcohols; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; | 2008 |
Etodolac attenuates mechanical allodynia in a mouse model of neuropathic pain.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitor | 2009 |
Etodolac blocks the allyl isothiocyanate-induced response in mouse sensory neurons by selective TRPA1 activation.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Calcium; Cells, Cultured; CHO Cells; Cricetinae | 2012 |
Secondary hypertrophic osteoarthropathy (HOA) mimicking primary HOA (pachydermoperiostitis or Touraine-Solente-Golé) syndrome.
Topics: Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Cyclooxygenase Inhibitors; Diagnosis, Differenti | 2004 |
Anti-inflammatory, antinociceptive, and gastric effects of Hypericum perforatum in rats.
Topics: Acetic Acid; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; | 2005 |
Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation.
Topics: Animals; Aspirin; Bradykinin; Bromelains; Cartilage, Articular; Cell Line; Concanavalin A; Depressio | 1994 |
Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs.
Topics: Acetates; Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Ca | 1994 |
Effects of the combined oral administration of NSAIDs and dextromethorphan on behavioral symptoms indicative of arthritic pain in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Beh | 1996 |
Etodolac: the role of a new NSAID in the management of arthritis and pain. Tenth Pan American Congress of Rheumatology and the Seventeenth Congress of the Mexican Society of Rheumatology. Guadalajara, Mexico, March 15, 1990.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Etodolac; Humans; Indoleacetic Acids; Pain | 1990 |